Halozyme Therapeutics (HALO)
Enables subcutaneous delivery of partner medicines through ENHANZE technology.
$112.71
vs last close−2.42 (−2.10%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 109.17% | 123.90M shares | |
|---|---|---|---|
| 688 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.26% | 1.43M shares | |
| 14 holders · as of Sep 17, 2026 | |||
| Adds to | 110.43% | ||
113.50M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.43%; nothing is left for Other.
13F, as of Jun 30, 2026
688 holders · 123.90M shares · 111 new positions · 379 increased · 209 reduced · 73 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.27M | 11.69% | +6.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.35M | 4.71% | +80.1K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.30M | 4.67% | +49.8K | Aug 13, 2026 |
| State Street Corp | 5.18M | 4.56% | +241.6K | Aug 7, 2026 |
| Invesco Ltd. | 3.18M | 2.80% | −834.5K | Aug 14, 2026 |
| Morgan Stanley | 2.83M | 2.50% | +270.3K | Aug 13, 2026 |
| Boston Partners | 2.77M | 2.44% | +89.9K | Aug 4, 2026 |
| Bank of America Corp /DE/ | 2.74M | 2.41% | −172.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.20% | 12.61M | 13G | Jul 17, 2025 |
| Vanguard Capital Management | 5.21% | 6.17M | 13G | Apr 30, 2026 |
| State Street Corporation | 5.20% | 6.64M | Oct 17, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Matthew L. Posarddirector | Sale · 4 lots | 18,996 | $107.74 | 58,839 |
| Sep 11, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 20,000 | $107.24 | 767,780 |
| Sep 10, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 20,000 | $107.17 | 767,780 |
| Sep 9, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 3 lots | 20,000 | $107.43 | 767,780 |
| Aug 19, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 3 lots | 20,000 | $107.00 | 767,780 |
| Aug 18, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 3 lots | 20,000 | $104.18 | 767,780 |
| Aug 17, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 5 lots | 20,000 | $102.60 | 767,780 |
| Aug 10, 2026 | Bernadette Connaughtondirector | Sale | 1,626 | $102.80 | 40,418 |
| Jul 8, 2026 | Helen Torleydirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 1,923 | $79.77 | 767,780 |
| Jul 1, 2026 | Bernadette Connaughtondirector | Sale · 2 lots | 1,625 | $76.71 | 42,044 |
House and Senate disclosures
Not reported.